Iovance Biotherapeutics
IOVA
87 hedge funds and large institutions have $345M invested in Iovance Biotherapeutics in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 16 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 93 → 87 (-6)
11% less capital invested
Capital invested by funds: $387M → $345M (-$41.9M)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
32% less call options, than puts
Call options by funds: $2.05M | Put options by funds: $3.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$20.9M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.99M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.88M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$1.81M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.46M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.16M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.96M |
| 4 |
QF
QVT Financial
New York
|
-$1.74M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.56M |
IOVA Hedge Fund Activity: Q4 2016 in Review
87 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2016, worth a combined $345M — down 11% from $387M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IOVA and 11 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 38 added.
The largest buyer was Franklin Resources, adding an estimated $20.9M. The largest seller was Fidelity Investments, cutting an estimated $7.46M.
- 87 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2016, down from 93 in Q3 2016.
- Funds reported $345M of Iovance Biotherapeutics stock for Q4 2016, down 11% quarter-over-quarter.
- 11 funds opened new Iovance Biotherapeutics positions in Q4 2016 and 16 closed out, a net change of -5 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2016 was Franklin Resources, an estimated $20.9M added.
- The largest Iovance Biotherapeutics seller in Q4 2016 was Fidelity Investments, an estimated $7.46M sold.
Based on aggregated 13F filings for Q4 2016.